Literature DB >> 11558831

Neurocardiogenic syncope: aetiology and management.

K A Gatzoulis1, P K Toutouzas.   

Abstract

Neurocardiogenic syncope is the most common cause of syncope presenting in the outpatient setting. It is usually encountered among individuals without an underlying heart disease, but not uncommonly participates in the syncope mechanism of patients with an obstructive or an arrhythmic cardiac cause for syncope as well. The vasovagal event is caused by a transient profound hypotensive reaction most commonly associated with inappropriate bradycardia resulting from activation of a complex autonomic reflex. The pathophysiology of neurocardiogenic syncope has been elucidated by tilt table testing, a noninvasive and well-tolerated method for reproducing the event in susceptible individuals. Although the majority of people with vasovagal fainting need no specific treatment, treatment is required for those presenting with problematic features such as frequent events accompanied by trauma or accidents, and occasionally by a severe cardioinhibitory pattern response. A number of different drugs have been proposed to favourably act on different aspects of the neurocardiogenic reflex but only a few randomised, placebo-controlled, drug-specific trials are currently available. Alternatively, cardiac pacing has also been introduced for patients who have symptoms that are drug-refractory or for those with a severe cardioinhibitory hypotensive response. The selection of the appropriate treatment plan should be individualised after consideration of patient history, clinical characteristics and preference, results of the baseline tilting study, and the existing evidence from the few randomised, controlled studies performed so far.

Entities:  

Mesh:

Year:  2001        PMID: 11558831     DOI: 10.2165/00003495-200161100-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  73 in total

1.  Recommendations for pacemaker prescription for symptomatic bradycardia. Report of a working party of the British Pacing and Electrophysiology Group.

Authors: 
Journal:  Br Heart J       Date:  1991-08

2.  The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope.

Authors:  S J Connolly; R Sheldon; R S Roberts; M Gent
Journal:  J Am Coll Cardiol       Date:  1999-01       Impact factor: 24.094

3.  Deglutition syncope and atrioventricular block selectively induced by hot food and liquid.

Authors:  R L Kunis; O B Garfein; A J Pepe; E M Dwyer
Journal:  Am J Cardiol       Date:  1985-02-15       Impact factor: 2.778

4.  Power spectrum analysis of heart rate variability to assess the changes in sympathovagal balance during graded orthostatic tilt.

Authors:  N Montano; T G Ruscone; A Porta; F Lombardi; M Pagani; A Malliani
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

5.  Head-upright tilt-table testing in evaluation and management of the malignant vasovagal syndrome.

Authors:  B P Grubb; P Temesy-Armos; J Moore; D Wolfe; H Hahn; L Elliot
Journal:  Am J Cardiol       Date:  1992-04-01       Impact factor: 2.778

6.  Biochemical changes involved in the mechanism of vasovagal syncope.

Authors:  A Theopistou; K Gatzoulis; E Economou; S Sideris; K Hantzos; C Stefanadis; P Toutouzas
Journal:  Am J Cardiol       Date:  2001-08-15       Impact factor: 2.778

7.  Malignant vasovagal syncope: a randomised trial of metoprolol and clonidine.

Authors:  M Biffi; G Boriani; P Sabbatani; G Bronzetti; L Frabetti; R Zannoli; A Branzi; B Magnani
Journal:  Heart       Date:  1997-03       Impact factor: 5.994

8.  Usefulness of fluoxetine hydrochloride for prevention of resistant upright tilt induced syncope.

Authors:  B P Grubb; D A Wolfe; D Samoil; P Temesy-Armos; H Hahn; L Elliott
Journal:  Pacing Clin Electrophysiol       Date:  1993-03       Impact factor: 1.976

9.  Efficacy of different treatment strategies for neurocardiogenic syncope.

Authors:  A Natale; J Sra; A Dhala; A Wase; M Jazayeri; S Deshpande; Z Blanck; M Akhtar
Journal:  Pacing Clin Electrophysiol       Date:  1995-04       Impact factor: 1.976

Review 10.  Cardiac pacing for prevention of recurrent vasovagal syncope.

Authors:  D G Benditt; M Petersen; K G Lurie; B P Grubb; R Sutton
Journal:  Ann Intern Med       Date:  1995-02-01       Impact factor: 25.391

View more
  4 in total

1.  Acupuncture-Associated Vasovagal Response: Revised Terminology and Hospital Experience.

Authors:  Kimberly A Christensen; Barbara J Gosse; Celia Hildebrand; Lynn A Gershan
Journal:  Med Acupunct       Date:  2017-12-01

2.  Correlation of noninvasive electrocardiography with invasive electrophysiology in syncope of unknown origin: implications from a large syncope database.

Authors:  Konstantinos A Gatzoulis; George Karystinos; Theodoros Gialernios; Helias Sotiropoulos; Andreas Synetos; Polychronis Dilaveris; Skevos Sideris; Ioannis Kalikazaros; Brian Olshansky; Christodoulos I Stefanadis
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-04       Impact factor: 1.468

3.  Permanent pacemaker implantation in unexplained syncope patients with borderline sinus bradycardia and electrophysiology study-proven sinus node disease.

Authors:  Ioannis Doundoulakis; Konstantinos A Gatzoulis; Petros Arsenos; Polychronis Dilaveris; Ioannis Skiadas; Dimitrios Tsiachris; Christos-Konstantinos Antoniou; Stergios Soulaidopoulos; George Karystinos; Voula Pylarinou; Maria Drakopoulou; Skevos Sideris; Charalambos Vlachopoulos; Dimitrios Tousoulis
Journal:  J Arrhythm       Date:  2020-11-22

4.  Syncope associated with supraventricular tachycardia: Diagnostic role of implantable loop recorders.

Authors:  Stergios Soulaidopoulos; Petros Arsenos; Ioannis Doundoulakis; Dimitrios Tsiachris; Christos-Konstantinos Antoniou; Polychronis Dilaveris; Nikolaos Fragakis; Melani Sotiriadou; Skevos Sideris; Athanasios Kordalis; Ageliki Laina; Dimitrios Tousoulis; Konstantinos Tsioufis; Konstantinos A Gatzoulis
Journal:  Ann Noninvasive Electrocardiol       Date:  2021-05-06       Impact factor: 1.468

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.